Skip to main content

Ipratropium Inhalation Solution Side Effects

Generic name: ipratropium

Medically reviewed by Drugs.com. Last updated on Mar 15, 2023.

Note: This document contains side effect information about ipratropium. Some dosage forms listed on this page may not apply to the brand name Ipratropium Inhalation Solution.

Applies to ipratropium: inhalation solution.

Serious side effects

Along with its needed effects, ipratropium (the active ingredient contained in Ipratropium Inhalation Solution) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking ipratropium:

More common

Less common

Rare

Incidence not known

Other side effects

Some side effects of ipratropium may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common or rare

For Healthcare Professionals

Applies to ipratropium: compounding powder, inhalation aerosol, inhalation solution.

General

The most common adverse reactions were bronchitis, COPD exacerbation, dyspnea, headache, throat irritation, cough, dry mouth, gastro-intestinal motility disorders (including constipation, diarrhea and vomiting), nausea, and dizziness.[Ref]

Respiratory

Very common (10% or more): Bronchitis (up to 14.6%), upper respiratory tract infection (up to 13.2%)

Common (1% to 10%): Chest pain, cough, dyspnea, bronchospasm, sputum increased, pharyngitis, rhinitis, sinusitis, throat irritation

Uncommon (0.1% to 1%): Paradoxical bronchospasm, laryngospasm, pharyngeal edema, dry throat[Ref]

Gastrointestinal

Common (1% to 10%): Mouth dryness, nausea, gastrointestinal motility disorder, dyspepsia

Uncommon (0.1% to 1%): Constipation, diarrhea, taste perversion, vomiting, stomatitis

Frequency not reported: Mouth edema[Ref]

Genitourinary

Common (1% to 10%): Urinary tract infection

Uncommon (0.1% to 1%): Urinary retention[Ref]

Musculoskeletal

Common (1% to 10%): Back pain

Uncommon (0.1% to 1%): Arthritis[Ref]

Nervous system

Common (1% to 10%): Headache, dizziness

Uncommon (0.1% to 1%): Tremor, nervousness[Ref]

Other

Common (1% to 10%): Influenza-like symptoms, pain[Ref]

Cardiovascular

Uncommon (0.1% to 1%): Hypertension, palpitations, supraventricular tachycardia

Rare (less than 0.1%): Atrial fibrillation, rate increased

Frequency not reported: Hypotension, palpitation, tachycardia[Ref]

Dermatologic

Uncommon (0.1% to 1%): Rash, pruritus

Rare (less than 0.1%): Urticaria[Ref]

Hypersensitivity

Uncommon (0.1% to 1%): Hypersensitivity, anaphylactic reactions, angioedema of tongue, lips, face

Frequency not reported: Urticaria (including giant urticaria), laryngospasm[Ref]

Ocular

Uncommon (0.1% to 1%): Blurred vision, mydriasis, intraocular pressure increased, glaucoma, eye pain, halo vision, conjunctival hyperemia, corneal edema

Rare (less than 0.1%): Accommodation disorder

Frequency not reported: Precipitation or worsening of narrow-angle glaucoma, acute eye pain[Ref]

References

1. Gross NJ. Ipratropium bromide. N Engl J Med. 1988;319:486-94.

2. Anderson WM. Hemodynamic and non-bronchial effects of ipratropium bromide. Am J Med. 1986;81:45-53.

3. Ipratropium. Med Lett Drugs Ther. 1987;29:71-2.

4. Massey KL, Gotz VP. Ipratropium bromide. Drug Intell Clin Pharm. 1985;19:5-12.

5. Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS. Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis. Drugs. 1980;20:237-66.

6. Product Information. Atrovent (ipratropium). Boehringer-Ingelheim. 2002.

7. Product Information. Atrovent (ipratropium). Boehringer-Ingelheim.

8. Cerner Multum, Inc. UK Summary of Product Characteristics.

9. Cerner Multum, Inc. Australian Product Information.

10. Levin DC, Little KS, Laughlin KR, Galbraith JM, Gustman PM, Murphy D, Kram JA, Hardie G, Reuter C, Ostransky D, Mcfarland K. Addition of anticholinergic solution prolongs bronchodilator effect of beta(2) agonists in patients with chronic obstructive pulmonary disease. Am J Med. 1996;100 Suppl:s40-8.

11. Lozewicz S. Bladder outflow obstruction induced by ipratropium bromide. Postgrad Med J. 1989;65:260-1.

12. Pras E, Stienlauf S, Pinkhas J, Sidi Y. Urinary retention associated with ipratropium bromide. DICP. 1991;25:939-40.

13. Verheijen-Breemhaar L, Bogaard JM, Hilvering C. Comparison of the bronchodilatory action and side-effects of ipratropium bromide and thiazinamium methyl sulphate: a long-term, double-blind, crossover trial in patients with chronic bronchitis. Pharmatherapeutica. 1982;3:180-7.

14. Braun SR, Levy SF. Comparison of ipratropium bromide and albuterol in chronic obstructive pulmonary disease: a three-center study. Am J Med. 1991;91:s28-32.

15. O'Driscoll BR. Supraventricular tachycardia caused by nebulised ipratropium bromide. Thorax. 1989;44:312.

16. Cabana MD, Johnson H, Lee CKK, Helfaer M. Transient anisocoria secondary to nebulized ipratropium bromide. Clin Pediat. 1998;37:445-7.

17. Kizer KM, Bess DT, Bedford NK. Blurred vision from ipratropium bromide. Am J Health Syst Pharm. 1999;56:914.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.